AxeroVision, Inc.

Quick facts

Phase 2 pipeline

• AXR-159
• AXR-270 High Dose
• AXR-270 Low Dose · Diabetes
  AXR-270 Low Dose is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AxeroVision, Inc. portfolio CI brief
• AxeroVision, Inc. pipeline updates RSS